NH Special Purpose Acquisition 17 Co. Ltd. (359090) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of NH Special Purpose Acquisition 17 Co. Ltd. KRW 3,436, price KRW 2,335, upside +47.1%, quality 45 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch NH Special Purpose Acquisition 17 Co. Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 1,699 KRW – 13,407 KRW · fair‑value band 2,577 KRW – 4,295 KRW · the 2,335 KRW price screens below the 3,436 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow NH Special Purpose Acquisition 17 Co. in your weekly email
Every Wednesday you see whether NH Special Purpose Acquisition 17 Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
C&R Research Inc. engages in the of clinical development for pharmaceuticals and medical devices. The company's therapeutic area comprises oncology, cardiovascular, endocrinology, dermatology, central nervous system, ophthalmology, and rare disease.The company was founded in 1997 and is based in Seoul, South Korea.
Stock analysis
NH Special Purpose Acquisition 17 Co. Ltd. (359090) currently trades at 2,335 KRW, while our model-based Fair Value estimate is 3,436 KRW, implying the stock looks roughly 32.0% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 7,112 KRW per share, and 13 of the 15 models we run sit above the 2,335 KRW price.
Bear case: the Economic Profit group reads lowest at 1,888 KRW, and 2 of the 15 models stay below the price. Evidence for this calculation is medium.
Scenario range: 2,577 KRW (bear) to 4,295 KRW (bull), the price of 2,335 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
NH Special Purpose Acquisition 17 Co. Ltd. reported revenue of 65.0B KRW in FY2025 versus 43.2B KRW in FY2021, a compound +10.8%/yr. Reported net income was 2.6B KRW in FY2025.
Key figures
Market cap 22.0B KRW (≈ $16.3M) · P/S ratio 0.35 · Dividend yield 2.1% · Net margin 4.0% · Return on equity 0.7% · Return on assets (EBIT) 5.7% · Operating margin −6.6% · Revenue (TTM) 62.7B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 57% below its 52-week high and 37% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 47%, 359090 screens cheaper than that median.
Fair Value models
Bear 2,577 KRWFair Value 3,436 KRWBull 4,295 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+8.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.7%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−17.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−19.7%
Dividend (yield on the price)2.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.0% → 2%
Compare NH Special Purpose Acquisition 17 Co. Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 133 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "NH Special Purpose Acquisition 17 Co. Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/359090
Frequently asked questions
Is NH Special Purpose Acquisition 17 Co. Ltd. (359090) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 3,436 KRW versus a price of 2,335 KRW, about +47% upside (undervalued).
What is the fair value of 359090?
Our model-based fair value for NH Special Purpose Acquisition 17 Co. Ltd. is 3,436 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 2,335 KRW.
What is the quality score of 359090?
NH Special Purpose Acquisition 17 Co. Ltd. has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for NH Special Purpose Acquisition 17 Co. Ltd. (359090)?
Our model-based price target is the fair value of 3,436 KRW (as of Sep 24, 2026) from 15 valuation models. Cautious scenario 2,577 KRW, optimistic scenario 4,295 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the NH Special Purpose Acquisition 17 Co. Ltd. stock forecast for 2026?
Our models put fair value at 3,436 KRW, about +47% upside versus a price of 2,335 KRW (undervalued). Cautious scenario 2,577 KRW, optimistic scenario 4,295 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of NH Special Purpose Acquisition 17 Co. Ltd. (359090)?
NH Special Purpose Acquisition 17 Co. Ltd. reported trailing-twelve-month revenue of about 62.7B KRW (latest available figure, as of Sep 24, 2026).
Does NH Special Purpose Acquisition 17 Co. Ltd. pay a dividend?
NH Special Purpose Acquisition 17 Co. Ltd. currently shows a dividend yield of about 2.14% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of NH Special Purpose Acquisition 17 Co. Ltd. (359090)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For NH Special Purpose Acquisition 17 Co. Ltd. it is 3,436 KRW per share (as of Sep 24, 2026), against a price of 2,335 KRW. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is NH Special Purpose Acquisition 17 Co. Ltd. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 359090 trades below its calculated fair value: price 2,335 KRW, fair value 3,436 KRW, a gap of about +47% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 359090?
No. The price is what the market pays today (2,335 KRW); the fair value is what the company's own numbers justify (3,436 KRW). For NH Special Purpose Acquisition 17 Co. Ltd. the two are 1,101 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is NH Special Purpose Acquisition 17 Co. Ltd. worth?
The market values NH Special Purpose Acquisition 17 Co. Ltd. at about 22.0B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 2,335 KRW; our models calculate a fair value of 3,436 KRW per share.
What do the bullish and bearish scenarios say about 359090?
Our models span a range for NH Special Purpose Acquisition 17 Co. Ltd.: cautious scenario 2,577 KRW, base 3,436 KRW, optimistic 4,295 KRW per share (as of Sep 24, 2026, price 2,335 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of NH Special Purpose Acquisition 17 Co. Ltd. (359090)?
Balance-sheet figures for NH Special Purpose Acquisition 17 Co. Ltd. (as of Sep 24, 2026): return on equity 0.7%. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is 359090 from its 52-week high?
NH Special Purpose Acquisition 17 Co. Ltd. trades at 2,335 KRW, about 57% below its 52-week high of 5,449 KRW and 37% above the low of 1,699 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 3,436 KRW is for.
Which stocks are comparable to NH Special Purpose Acquisition 17 Co. Ltd.?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is NH Special Purpose Acquisition 17 Co. Ltd. stock attractive at the current price?
The data as of Sep 24, 2026: price 2,335 KRW, calculated fair value 3,436 KRW (+47%), Quality Score 45/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 359090 calculated?
We run NH Special Purpose Acquisition 17 Co. Ltd. through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 3,436 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9 % above its aggregate fair value. NH Special Purpose Acquisition 17 Co. Ltd. currently trades 47 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of NH Special Purpose Acquisition 17 Co. Ltd. (359090)?
The closing price on Sep 23, 2026 was 2,335 KRW. Our model-based fair value is 3,436 KRW, about +47% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with NH Special Purpose Acquisition 17 Co. Ltd. right now?
The price is below even our cautious bear case (2,577 KRW). The market is more pessimistic than our downside scenario. Solid quality (45/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of NH Special Purpose Acquisition 17 Co. Ltd.
How large is the market capitalisation of NH Special Purpose Acquisition 17 Co. Ltd. (359090)?
The market capitalisation of NH Special Purpose Acquisition 17 Co. Ltd. is 22.0B KRW (≈ $16.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of NH Special Purpose Acquisition 17 Co. Ltd. (359090)?
The price-to-sales ratio of NH Special Purpose Acquisition 17 Co. Ltd. is 0.35 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of NH Special Purpose Acquisition 17 Co. Ltd. (359090)?
The dividend yield of NH Special Purpose Acquisition 17 Co. Ltd. is 2.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of NH Special Purpose Acquisition 17 Co. Ltd. (359090)?
The net margin of NH Special Purpose Acquisition 17 Co. Ltd. is 4.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of NH Special Purpose Acquisition 17 Co. Ltd. (359090)?
The return on equity (ROE) of NH Special Purpose Acquisition 17 Co. Ltd. is 0.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of NH Special Purpose Acquisition 17 Co. Ltd. (359090)?
On an EBIT basis the return on assets of NH Special Purpose Acquisition 17 Co. Ltd. is 5.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of NH Special Purpose Acquisition 17 Co. Ltd. (359090)?
The operating margin of NH Special Purpose Acquisition 17 Co. Ltd. is −6.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at NH Special Purpose Acquisition 17 Co. Ltd. (359090)?
Revenue at NH Special Purpose Acquisition 17 Co. Ltd. is growing −13.4% versus a year earlier (3y avg +10.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at NH Special Purpose Acquisition 17 Co. Ltd. (359090)?
Earnings per share at NH Special Purpose Acquisition 17 Co. Ltd. are growing −47.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does NH Special Purpose Acquisition 17 Co. Ltd. (359090) generate?
The free cash flow of NH Special Purpose Acquisition 17 Co. Ltd. is −3.4B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does NH Special Purpose Acquisition 17 Co. Ltd. (359090) carry?
The net debt of NH Special Purpose Acquisition 17 Co. Ltd. is 911M KRW (fiscal year 2022). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch NH Special Purpose Acquisition 17 Co. Ltd. in the live analysis
One click puts NH Special Purpose Acquisition 17 Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
